Latest From Isogenica Ltd.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Isogenica Ltd.
- Senior Management
- Guy Hermans, PhD, CSO
- Contact Info
Phone: (44) 1799 533680
Chesterford Research Park
Little Chesterford, CB10 1XL
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.